News
Quantumpharm Inc., known as Xtalpi Inc., announced receiving $51 million up front from a potential $5.99 billion deal with ...
A management-led syndicate of prominent investors acquired a majority stake in Histosonics Inc. that values the company at ...
With half-year industry financings down 59% from last year, and a U.S. administration supportive of cryptocurrencies, ...
The U.S. Federal Trade Commission (FTC) reported Aug. 6 that it will try to block Edwards Lifesciences Corp.’s proposed ...
Location, location, location. While location is as important in manufacturing as it is in buying a home, it could become even ...
A federal appeals court opened the door Aug. 6 for an amended class-action lawsuit alleging that Astrazeneca plc, Eli Lilly ...
The difference between the origin of Alzheimer's disease (AD) and its symptoms is an obstacle to finding effective treatments ...
Infectious disease biopharma stocks bounced back in June and July, with the BioWorld Infectious Disease Index (BIDI) closing July up 4.34%. This marked a sharp reversal from earlier in the year, as ...
Innogen Pharmaceutical Group announced an $86 million IPO on the Hong Kong Stock Exchange that will see the company advance its lead product, Diabegone (efsubaglutide alfa), an ultra-long-acting ...
Rivo Bio Inc. has disclosed compounds acting as 5-HT2A receptor agonists reported to be useful for the treatment of depression, schizophrenia and anxiety disorders.
Hefei Institutes of Physical Science Chinese Academy of Sciences has synthesized phosphoglycerate kinase 1 (PGK1) inhibitors reported to be useful for the treatment of inflammatory bowel disease.
Pharmaceutical Technology Co. Ltd., Quanzhou Haichuang Pharmaceutical Technology Co. Ltd. and Suzhou Grandkol Pharm Technology Co. Ltd. have discovered new compounds.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results